I guess this is the plan: Successful completion of this financing will provide us with capital to continue our development efforts, pursue regulatory approvals and commercialization of the point-of-care rapid test format of our RECAF(TM) cancer marker testing technology, and to commence marketing our other test formats in sectors where regulatory approvals are not required.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.